Payment overview · 2025
General Payments
$342.02
12 reported records · 8 companies
Healthcare provider profile · identity verified
Andres Gonzalez, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MONTCLAIR, CA · NPI 1669892147
Verified facts
What the public records show
CMS Open Payments records show Andres Gonzalez, M.D. received $342.02 in general payments during 2025 across 12 reported records.
GlaxoSmithKline, LLC. accounted for 29.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $101.41 | 29.6% | 4 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $82.70 | 24.2% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $35.84 | 10.5% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $33.04 | 9.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $32.30 | 9.4% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.23 | 5.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.50 | 5.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.00 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $342.02 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $101.41 | 4 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $82.70 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $35.84 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $33.04 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $32.30 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 360 | 108 |
| Furosemide | Furosemide | 204 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 199 | 69 |
| Eliquis | Apixaban | 182 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 182 | 38 |
| Gabapentin | Gabapentin | 176 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 149 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 138 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 46 |
| Metformin Hcl | Metformin Hcl | 129 | 43 |
| Losartan Potassium | Losartan Potassium | 111 | 42 |
| Lisinopril | Lisinopril | 109 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 25 |
| Carvedilol | Carvedilol | 78 | 29 |
| Lorazepam | Lorazepam | 78 | 23 |
| Divalproex Sodium | Divalproex Sodium | 75 | 20 |
| Trazodone Hcl | Trazodone Hcl | 73 | 15 |
| Potassium Chloride | Potassium Chloride | 68 | 15 |
| Omeprazole | Omeprazole | 61 | 25 |
| Levetiracetam | Levetiracetam | 57 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 23 |
| Risperidone | Risperidone | 56 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 20 |
| Meloxicam | Meloxicam | 55 | 17 |
| Donepezil Hcl | Donepezil Hcl | 53 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 14 |
| Sertraline Hcl | Sertraline Hcl | 52 | 15 |
| Famotidine | Famotidine | 50 | 21 |
| Cephalexin | Cephalexin | 49 | 44 |
| Mirtazapine | Mirtazapine | 49 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 46 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 11 |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Ozempic | Semaglutide | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 15 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Simvastatin | Simvastatin | 39 | suppressed |
| Glipizide | Glipizide | 38 | 12 |
| Tramadol Hcl | Tramadol Hcl | 38 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | 17 |
| Alprazolam | Alprazolam | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 30 |
| Amiodarone Hcl | Amiodarone Hcl | 34 | 11 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 34 | 12 |
| Ibuprofen | Ibuprofen | 34 | 13 |
| Lactulose | Lactulose | 34 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | suppressed |
| Olanzapine | Olanzapine | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 24 |
| Sucralfate | Sucralfate | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 12 |
| Latanoprost | Latanoprost | 28 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 28 | 18 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | 19 |
| Prednisone | Prednisone | 27 | 22 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 26 | 15 |
| Spironolactone | Spironolactone | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | 11 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 25 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 11 |
| Naloxone Hcl | Naloxone Hcl | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Novolin R | Insulin Regular, Human | 23 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Humulin R | Insulin Regular, Human | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Vancomycin Hcl | Vancomycin Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 12 |
| Brilinta | Ticagrelor | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Glucagon Emergency Kit | Glucagon | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Ertapenem | Ertapenem Sodium | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Apidra Solostar | Insulin Glulisine | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Teriflunomide | Teriflunomide | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $342.02 · 12 records | GlaxoSmithKline, LLC. | DUPIXENT, Dexcom G6 Transmitter, Kerendia, NUCALA, Prolastin-C Liquid, TZIELD, YUPELRI, Zunveyl | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with SANOFI-AVENTIS U.S. LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error